Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duvakitug
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Duvakitug is a human IgG1-λ2 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15 (TNFSF15). TL1A signaling amplifies inflammation and drives fibrosis in inflammatory bowel disease (IBD) by binding to its receptor DR3. By inhibiting TL1A signaling via DR3, duvakitug aims to reduce the overactive immune response and fibrotic processes associated with IBD. Duvakitug has demonstrated efficacy and favorable safety as an induction treatment in adults with moderately to severely active ulcerative colitis and Crohn’s disease in phase 2b clinical trials. It is being developed through a collaboration between Teva Pharmaceutical Industries and Sanofi, with plans for phase 3 development pending regulatory discussions[1][2][4][6][7].
- Brand names
- duvakitug
- Other names
- TEV-48574TEV48574TEV 48574TEV’574SAR447189SAR-447189SAR 447189
02
Targets
Beyond the preview
Go deeper on duvakitug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on duvakitug.